Mayne Pharma in Plunge into US Drugs Market
Mayne Pharma has moved to lift its presence in the US drugs market with the $890 million ($US652 million) acquisition of a suite of drugs from Israel’s Teva Pharmaceuticals.
The buy will be funded by a placement and share issue which will lift Mayne’s sharemarket worth by more than 40 per cent to close to $2 billion. The Australian Financial Review’s Street Talk column revealed the raising details on Monday night. Sydney Morning Herald – Read more…